WuXi Biologics (Cayman) Inc. Stock
Equities
2269
KYG970081173
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.38 HKD | -7.21% |
|
-12.25% | -3.37% |
| 06-05 | Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub | CI |
| 05-31 | Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth | RE |
| Capitalization | 117B 135B 17.27B 14.96B 13.72B 12.91B 24.05B 1,646B 24.43B 163B 63.49B 796B 64.85B 63.44B 2,768B | P/E ratio 2026 * |
21.4x | P/E ratio 2027 * | 17.7x |
|---|---|---|---|---|---|
| Enterprise value | 106B 122B 15.61B 13.52B 12.4B 11.67B 21.73B 1,487B 22.07B 147B 57.37B 719B 58.6B 57.33B 2,501B | EV / Sales 2026 * |
4.19x | EV / Sales 2027 * | 3.47x |
| Free-Float |
90.02% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: WuXi Biologics (Cayman) Inc.
| 1 day | -7.21% | ||
| 1 week | -12.25% | ||
| Current month | -8.88% | ||
| 1 month | -6.98% | ||
| 3 months | -14.23% | ||
| 6 months | -7.77% | ||
| Current year | -3.37% |
| 1 week | 30.24 |  | 35.46 |
| 1 month | 30.24 | | 35.46 |
| Current year | 30.24 | | 44 |
| 1 year | 23.1 | | 44 |
| 3 years | 10.14 | | 52.45 |
| 5 years | 10.14 | | 148 |
| 10 years | 8.33 | | 148 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 54 | 2015-12-31 |
Ming Tu
DFI | Director of Finance/CFO | 56 | 2021-08-22 |
Xuejun Gu
CTO | Chief Tech/Sci/R&D Officer | 55 | 2024-03-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Ge Li
CHM | Chairman | 59 | 2014-01-31 |
Zhi Sheng Chen
BRD | Director/Board Member | 54 | 2014-01-31 |
Yan Ling Cao
BRD | Director/Board Member | 42 | 2016-04-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01-19 | Wuxi Biologics Holdings Ltd.
| Other | Company | 150,000,000 | 3.6336% | |
| 12-01 | Other | Chief Technology Officer | 41,638 | 0.0010% | ||
| 11-27 | Other | Chief Executive Officer | 1,563,177 | 0.0385% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.21% | -12.25% | +16.85% | -30.24% | 17.27B | |
| +0.05% | +6.74% | +49.28% | +110.26% | 55.01B | |
| -0.20% | -4.96% | +50.88% | +52.59% | 43.37B | |
| -1.69% | -8.20% | -18.81% | -19.50% | 22.27B | |
| -10.20% | -11.87% | +27.98% | +376.34% | 20.42B | |
| +2.15% | -1.25% | +8.26% | -39.79% | 15.02B | |
| +0.40% | +4.40% | +22.47% | +173.48% | 13.25B | |
| -2.90% | -12.26% | +11.05% | - | 11.71B | |
| -0.47% | -15.79% | -28.27% | +685.64% | 11.46B | |
| -1.19% | -2.07% | +75.03% | +76.14% | 11.23B | |
| Average | -2.00% | -5.34% | +21.47% | +153.88% | 22.1B | |
| Weighted average by Cap. | -1.64% | -2.90% | +29.09% | +121.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 25.22B 29.17B 3.72B 3.22B 2.96B 2.78B 5.18B 355B 5.27B 35.17B 13.69B 172B 13.98B 13.68B 597B | 29.59B 34.23B 4.37B 3.78B 3.47B 3.27B 6.08B 416B 6.18B 41.26B 16.06B 201B 16.4B 16.05B 700B |
| Net income | 5.5B 6.36B 811M 703M 645M 607M 1.13B 77.32B 1.15B 7.66B 2.98B 37.39B 3.05B 2.98B 130B | 6.65B 7.7B 982M 851M 780M 734M 1.37B 93.59B 1.39B 9.28B 3.61B 45.26B 3.69B 3.61B 157B |
| Net Debt | -11.28B -13.04B -1.66B -1.44B -1.32B -1.24B -2.32B -159B -2.35B -15.72B -6.12B -76.73B -6.25B -6.12B -267B | -14.43B -16.69B -2.13B -1.84B -1.69B -1.59B -2.97B -203B -3.01B -20.12B -7.83B -98.17B -8B -7.82B -341B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-08 | 30.38 $ | -7.21% | 52,613,786 |
| 26-06-05 | 32.74 $ | +0.99% | 24,572,700 |
| 26-06-04 | 32.42 $ | -0.80% | 20,497,560 |
| 26-06-03 | 32.68 $ | -7.00% | 45,782,870 |
| 26-06-02 | 35.14 $ | +1.50% | 26,521,980 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2269 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition